SG11202003910VA - ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS - Google Patents
ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITISInfo
- Publication number
- SG11202003910VA SG11202003910VA SG11202003910VA SG11202003910VA SG11202003910VA SG 11202003910V A SG11202003910V A SG 11202003910VA SG 11202003910V A SG11202003910V A SG 11202003910VA SG 11202003910V A SG11202003910V A SG 11202003910VA SG 11202003910V A SG11202003910V A SG 11202003910VA
- Authority
- SG
- Singapore
- Prior art keywords
- hutnfr1
- therapy
- nonalcoholic steatohepatitis
- nonalcoholic
- steatohepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203853 | 2017-11-27 | ||
| PCT/EP2018/082634 WO2019102023A1 (en) | 2017-11-27 | 2018-11-27 | ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003910VA true SG11202003910VA (en) | 2020-06-29 |
Family
ID=60473433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003910VA SG11202003910VA (en) | 2017-11-27 | 2018-11-27 | ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11028178B2 (en) |
| EP (1) | EP3717068A1 (en) |
| JP (1) | JP7280259B2 (en) |
| KR (1) | KR20200089699A (en) |
| CN (1) | CN111787980A (en) |
| AU (1) | AU2018371232A1 (en) |
| BR (1) | BR112020010632A2 (en) |
| CA (1) | CA3081493A1 (en) |
| EA (1) | EA202091182A1 (en) |
| IL (1) | IL274770A (en) |
| MX (1) | MX2020005445A (en) |
| SG (1) | SG11202003910VA (en) |
| TW (1) | TW201925234A (en) |
| WO (1) | WO2019102023A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4006269A1 (en) | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antibody which binds to tumour necrosis factor receptors |
| WO2007058894A2 (en) * | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| EP1972637B1 (en) | 2007-03-19 | 2011-06-29 | Universität Stuttgart | huTNFR1 selective antagonists |
| PL2616489T3 (en) | 2010-09-16 | 2017-07-31 | Baliopharm Ag | Anti-hutnfr1 antibody |
| CN105121460A (en) * | 2013-03-06 | 2015-12-02 | 波塔力克斯有限公司 | Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy |
| SG11201808680RA (en) | 2016-04-05 | 2018-11-29 | Univ Stuttgart | MONOVALENT INHIBITOR OF huTNFR1 INTERACTION |
-
2018
- 2018-11-27 WO PCT/EP2018/082634 patent/WO2019102023A1/en unknown
- 2018-11-27 SG SG11202003910VA patent/SG11202003910VA/en unknown
- 2018-11-27 EA EA202091182A patent/EA202091182A1/en unknown
- 2018-11-27 KR KR1020207017059A patent/KR20200089699A/en unknown
- 2018-11-27 CN CN201880087298.0A patent/CN111787980A/en active Pending
- 2018-11-27 CA CA3081493A patent/CA3081493A1/en active Pending
- 2018-11-27 TW TW107142234A patent/TW201925234A/en unknown
- 2018-11-27 US US16/766,841 patent/US11028178B2/en active Active
- 2018-11-27 EP EP18812110.7A patent/EP3717068A1/en active Pending
- 2018-11-27 JP JP2020528930A patent/JP7280259B2/en active Active
- 2018-11-27 AU AU2018371232A patent/AU2018371232A1/en active Pending
- 2018-11-27 BR BR112020010632-1A patent/BR112020010632A2/en not_active Application Discontinuation
- 2018-11-27 MX MX2020005445A patent/MX2020005445A/en unknown
-
2020
- 2020-05-19 IL IL274770A patent/IL274770A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200299396A1 (en) | 2020-09-24 |
| IL274770A (en) | 2020-07-30 |
| JP7280259B2 (en) | 2023-05-23 |
| KR20200089699A (en) | 2020-07-27 |
| CN111787980A (en) | 2020-10-16 |
| AU2018371232A1 (en) | 2020-05-21 |
| TW201925234A (en) | 2019-07-01 |
| MX2020005445A (en) | 2020-10-28 |
| EP3717068A1 (en) | 2020-10-07 |
| BR112020010632A2 (en) | 2020-11-10 |
| EA202091182A1 (en) | 2020-07-29 |
| US11028178B2 (en) | 2021-06-08 |
| CA3081493A1 (en) | 2019-05-31 |
| JP2021504379A (en) | 2021-02-15 |
| WO2019102023A1 (en) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| HK1225968A1 (en) | Combination therapy for treatment of hbv infections | |
| ZA201807083B (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| EP3691534C0 (en) | Ultrasound therapy | |
| SG11201608077PA (en) | Treatment of nafld and nash | |
| EP3445385A4 (en) | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) | |
| GB201707153D0 (en) | Therapy | |
| ZA201805634B (en) | Conjugate of therapeutic enzymes | |
| IL285882A (en) | Therapeutic uses of l-4-chlorokynurenine | |
| HK1258128A1 (en) | Selection of patients for combination therapy | |
| GB201708663D0 (en) | Therapy | |
| GB201719646D0 (en) | Therapy | |
| IL271236A (en) | Licofligozin for the treatment of non-alcoholic steatohepatitis | |
| PT3475425T (en) | Treatments of non-alcoholic steatohepatitis (nash) | |
| IL274770A (en) | Anti-hutnfr1 therapy of nonalcoholic steatohepatitis | |
| IL276421A (en) | Methods of testosterone therapy | |
| IL289338A (en) | Therapeutic interactions of leucomethylthioninium | |
| IL274748A (en) | Improved treatment of cancer | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| GB201711769D0 (en) | Methods of cancer therapy | |
| GB201715430D0 (en) | Therapy | |
| GB201707945D0 (en) | Cnacer therapy | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201707183D0 (en) | Macrophage-based therapy | |
| GB201703857D0 (en) | Treatment of cancer |